Health Care • Biotechnology: Commercial Physical & Biological Resarch
$12.10 ▲ +0.22
(+1.85%)
MKT CAP: $2.08B • VOL: 4.34M
52W L $2 52W H $13
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$10
MEDIAN
$14
MEAN
$14
HIGH
$16
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ABSI TAPE
ABSI // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $14.64 | $13.91 | 2025-02-14 | $11.01 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $15.25 | $14.28 | 2025-02-06 | $11.37 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $13.79 | $13.31 | 2025-01-29 | $11.62 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $12.34 | — | 2025-01-17 | $11.86 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $10.65 | $11.49 | 2025-01-09 | $10.77 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $14.40 | $12.58 | 2024-12-18 | $10.53 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $11.74 | $12.22 | 2024-12-04 | $11.25 | -4.3% | 48% | C |